Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 83 results for bevacizumab

  1. NICE concluded that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema secondary to retinal vein occlusion should be conducted.

    directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema secondary to retinal...

    Research recommendation
    Published
    9 June 2015

  2. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    14 September 2022
    View recommendations

    Sections for TA824

  3. Regorafenib for previously treated metastatic colorectal cancer (TA866)

    Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    8 February 2023
    View recommendations

    Sections for TA866

  4. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6428

    Awaiting development [GID-TA11538] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the

    Diagnostics guidance
    Published
    10 December 2014
    View recommendations

    Sections for DG16

  6. Bevacizumab for treating recurrent glioblastoma [ID978]

    Discontinued [GID-TA10149]

    Technology appraisal guidance
    Discontinued

  7. Bevacizumab for the treatment of recurrent glioblastoma multiforme [ID80]

    Discontinued [GID-TAG413]

    Technology appraisal guidance
    Discontinued

  8. Bevacizumab for untreated malignant pleural mesothelioma [ID1183]

    Discontinued [GID-TA10197]

    Technology appraisal guidance
    Discontinued

  9. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued [GID-TAG432]

    Technology appraisal guidance
    Discontinued

  10. Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.

    Technology appraisal guidance
    Published
    8 September 2021
    View recommendations

    Sections for TA724

  11. Tivozanib for treating advanced renal cell carcinoma (TA512)

    Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    21 March 2018
    View recommendations

    Sections for TA512

  12. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

    Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.

    Technology appraisal guidance
    Published
    17 October 2018
    View recommendations

    Sections for TA544

  13. Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]

    Discontinued [GID-TA11205]

    Technology appraisal guidance
    Discontinued

  14. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development [GID-TAG406] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Erlotinib in combination with bevacizumab for the maintenance treatment of advanced or metastatic non-small cell lung cancer [ID44]

    Discontinued [GID-TA11206]

    Technology appraisal guidance
    Discontinued